Health Care Supplies

Fuerjia

Fuerjia released FY2026 Q1 earnings on April 22 After-Market BJT, actual revenue CNY 548.29 M, actual EPS CNY 0.33

Fuerjia released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 1.893 B (forecast CNY 2.014 B), actual EPS CNY 0.83 (forecast CNY 1.02)

Fuerjia released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 596 M, actual EPS CNY 0.205

Fuerjia to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

Fuerjia to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 2.014 B, EPS CNY 1.02

Fuerjia released FY2025 9 Months earnings on October 23 After-Market (BJT), actual revenue CNY 1.297 B, actual EPS CNY 0.6238

Fuerjia released FY2025 Q3 earnings on October 23 After-Market BJT, actual revenue CNY 434.04 M, actual EPS CNY 0.1847

Fuerjia FY2025 Q3 Earnings Release Scheduled for October 24, After-Market BJT

Fuerjia released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 863.11 M, actual EPS CNY 0.4437

Fuerjia released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 562.05 M, actual EPS CNY 0.2622

Fuerjia to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Tianfeng Securities Rates Furijia 'Buy'

Fuergia's Recombinant Type III Humanized Collagen Protein Freeze-dried Fiber is in Clinical Trial Phase

Fujiera's Recombinant Human-like Collagen Protein Patch Passes Ethics Review and Enters Clinical Trial

TF Securities Maintains Buy Rating for Fuerjia

Fujir 佳 Responds to Shareholder Numbers and Marketing Expenses

TF Securities Issues a Buy Rating for Furijia

Fujiera Responds to Investor Inquiry on Ergothioneine R&D Plans

Fujiera Reassures Investors of Quality Improvements

Furijia Faces Market Competition and Slowing Growth

Ordinary dividend (cash)

Ex Date: 2026.05.25, Cash dividend 0.8 CNY

301371

Wallstreetcn

Bloomage Biotech

Shanghai Jahwa

GIANT BIOGENE

Fuerjia's 2 Billion Ceiling: The Restructuring Test After Channel Dividends Fade

According to the Zhitong Finance APP, Fuerjia released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.297 billion yuan, a year-on-year decrease of 11.54%. The net profit attributable to shareholders of the listed company was 325 million yuan, a year-on-year decrease of 36.73%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 254 million yuan, a year-on-year decrease of 48.20%. The basic earnings per share were 0.625 yuan

Zhitong

Fuerjia released its performance for the first three quarters, with a net profit attributable to the parent company of 325 million yuan, a decrease of 36.73%

Fuerjia released its semi-annual report for 2025, with operating revenue of 863 million yuan, a year-on-year decrease of 8.15%; net profit attributable to the parent company was 230 million yuan, a year-on-year decline of 32.54%. The net profit after deducting non-recurring gains and losses was 166 million yuan, a year-on-year decrease of 48.66%. The basic earnings per share were 0.44 yuan. The decline in operating revenue was mainly due to the optimization of offline channels, while the decrease in net profit was attributed to increased promotional expenses

Fuerjia released its performance for the first half of the year, with a net profit attributable to the parent company of 230 million yuan, a decrease of 32.54%

On June 26th, Fuerjia announced that the company's board of directors convened on the same day to approve the appointment of Zhang Chunjing as the assistant general manager of the company, with a term starting from the date of the board's approval until the end of the second board's term. Zhang Chunjing possesses the capability to serve as a senior management personnel of a listed company, and her qualifications meet the requirements for senior management personnel of a listed company

Fuerjia: Appointed Zhang Chun Jing as the Assistant General Manager of the company

600223

603630

603983

300886

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%, and Lafang, Fuerjia, Freda, Marubi, and others following suit

Freda

Lafang

Marubi

Hyea Aromas

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%

Fuerjia announced that its research and development product "Recombinant Type III Humanized Collagen Dressing" has completed clinical trial filing, obtained ethical review approval, and has been filed with the Heilongjiang Provincial Drug Administration. This product will be used for the efficacy and safety evaluation of skin barrier function repair in patients with skin wounds after laser and photon procedures, as well as those with sensitive skin

Fuerjia: The clinical trial filing for the restructured Type III humanized collagen dressing has been completed

301520

603896

002243

Ergothioneine has recently attracted market attention, with several listed companies responding to related questions on interactive platforms. CITIC Securities' research report points out that ergothioneine has promising prospects in synthetic biology new materials. LEAGUER's equity investee, Ruidelin, has obtained Self-GRAS certification for ergothioneine; AHWB is collaborating with Sanofi on clinical projects; Shouxiangu's ergothioneine has natural antioxidant properties; Fuerjia's products contain ergothioneine ingredients

AHWB

Shouxiangu

LEAGUER

CITIC SEC

Ergothioneine receives attention, multiple listed companies respond to related questions

Fuerjia stated on the interactive platform that the company currently has no technology for producing ergotamine

Fuerjia: The company currently has no technology for producing ergotamine

Fuerjia released its 2024 annual report, with operating revenue of 2.017 billion yuan, a year-on-year increase of 4.32%. The net profit attributable to shareholders was 661 million yuan, a year-on-year decrease of 11.77%. The net profit after deducting non-recurring gains and losses was 604 million yuan, a year-on-year decrease of 17.00%. The basic earnings per share were 1.65 yuan. The company plans to distribute a cash dividend of 10 yuan for every 10 shares to all shareholders and to increase capital reserves by issuing 3 additional shares for every 10 shares to all shareholders

Fuerjia released its 2024 annual performance, with a net profit attributable to the parent company of 661 million yuan, a decrease of 11.77%

According to the Zhitong Finance APP, Fuerjia released its first quarter report for 2025, with operating revenue of 301 million yuan, a year-on-year decrease of 26.39%. The net profit attributable to shareholders of the listed company was 91.3843 million yuan, a year-on-year decrease of 39.77%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 52.6354 million yuan, a year-on-year decrease of 62.82%. The basic earnings per share were 0.23 yuan

Fuerjia released its first-quarter performance, with a net profit attributable to the parent company of 91.3843 million yuan, a decrease of 39.77%

Fuerjia(301371.SZ)